Spyre Therapeutics, Inc.

NASDAQ:SYRE

Biotechnology

Healthcare
$101.46 +1.38%

+$1.21 today

Market cap
$9.64B
Beta
3.06
P/E (TTM)
-171.1
EPS (TTM)
-$0.52
52W Low $14.00High $91.04

Volume 1.37M

Average 1.17M

SYRE Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

Spyre Therapeutics, Inc.NASDAQ: SYRE

Accounts Payables · Q3 FY2026 · quarter ended Sep 2026

Accounts payables dips below year-ago levels

Q3 FY2026 accounts payables of $3.74M fell 0.0% year over year, behind the +112.4% change in trailing-twelve-month accounts payables. Sequentially, it rose 12380.0% from the prior quarter.

Context

  • Accounts payables increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -0.0% toward the trailing-twelve-month pace of +112.4%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
$3.74M+12380.0% QoQ
Last fiscal yearDec 2025
$7.65M+3425.7% YoY
LTMSep 2026
$1.46M+112.4% YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-0.0%——
1 year+3425.7%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Payables history

USD · from the cash flow

Latest · FY2025
7.65M USD
Year-over-year change
+3425.7%
4-year CAGR
+63.7%

Accounts Payables vs competitors

How SYRE compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts payables is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +112.4% is the 4th highest of 7, against a peer median of +193.1%.
  • Accounts payables amounts to 1.6% of revenue for SYRE, versus a peer median of 90.5%.
SYRE Competitors
Accounts Payables for SYRE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ANABAnaptysBio, Inc.LTM Mar 2026$81.11M USD+53.9%—34.9%
ARDXArdelyx, Inc.LTM Mar 2026$14.47M USD+507.1%-21.1%3.4%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$8.3M USD+286.2%+184.2%99.2%
IFRXInflaRx N.V.LTM Mar 2026€6.32M EUR—+17.8%21552.6%
IMUXImmunic, Inc.LTM Mar 2026$4.41M USD+702.6%+15.7%—
UPBUpstream Bio, Inc.LTM Mar 2026$3.01M USD-190.0%—90.5%
SYRESpyre Therapeutics, Inc.LTM Sep 2026$1.46M USD+112.4%—1.6%
ABVXAbivax S.A.FY2025€0 EUR+100.0%——
ODTXOdyssey Therapeutics, Inc.—— ———
AGMBAgomAb Therapeutics N.V. American Depositary Shares—— ———
Peer median (excluding SYRE) —+193.1%+16.7%90.5%

Competitors are the stored peer set for SYRE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(65.8M)(83.82M)(338.79M)(208.02M)(155.2M)
Depreciation & Amortization1.58M1.96M744K010M
Deferred Income Tax0(327K)000
Stock-Based Compensation8.04M7.11M25.68M44.83M37.61M
Change in Working Capital1.83M(5.5M)(5.21M)(4.53M)(5.93M)
Accounts Receivables(815K)440K375K00
Inventory0(440K)000
Accounts Payables1.07M(2.64M)218K(230K)7.65M
Other Working Capital1.58M(2.86M)(5.8M)(4.3M)(13.58M)
Other Non-Cash Items638K426K217.67M10.31M(55.73M)
Operating Cash Flow(53.72M)(80.14M)(99.91M)(157.41M)(169.25M)
Capital Expenditures(573K)(38K)000
Acquisitions (Net)003.04M00
Purchases of Investments(133.08M)(39.5M)(166.8M)(599.25M)(522.21M)
Sales of Investments111.03M96.55M39.9M245.97M371.74M
Other Investing Activities0015.48M07M
Investing Cash Flow(22.62M)57.01M(108.39M)(353.29M)(143.48M)
Debt Repayment(510K)(418K)(16K)00
Common Stock Issued042.87M169.11M236.38M314.44M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities1.9M222K(5.38M)5.67M(5.41M)
Financing Cash Flow1.39M42.68M361.08M410.91M309.03M
Effect of Forex Changes(15K)(106K)25K(3K)0
Net Change in Cash(74.96M)19.44M152.8M(99.79M)(3.7M)
Free Cash Flow(54.29M)(80.18M)(99.91M)(157.41M)(169.25M)

Spyre Therapeutics, Inc.

NASDAQ:SYRE

Intrinsic Alpha fair value

Locked

Current Price

$101.46

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.